Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers (HESTIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01135017
Recruitment Status : Terminated
First Posted : June 2, 2010
Results First Posted : April 1, 2013
Last Update Posted : April 11, 2013
Sponsor:
Information provided by (Responsible Party):
Sanofi

Brief Summary:

Primary objective was to evaluate the effects of dronedarone on Atrial Fibrillation (AF) burden (i.e. percent time in AF) as measured on electrogram (EGM) in subjects with a permanent pacemaker.

Secondary objectives were to evaluate:

  • the effects of dronedarone on AF pattern characteristics i.e. ventricular rate during AF;
  • the effects of dronedarone on subject-perceived AF burden and symptom severity as reported by subjects using the Atrial Fibrillation Severity Scale (AFSS);
  • the incidence of electrical cardioversion (or overdrive pacing) during treatment;
  • the safety of dronedarone.

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Drug: Dronedarone Drug: Placebo (for Dronedarone) Phase 4

Detailed Description:
The maximum duration of the study period for a participant was 18 weeks (approximatively 4.5 months) including up to 4 weeks screening, 12-week Treatment period and a post-treatment follow-up of 2 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 112 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Assess the Effects of Dronedarone 400 mg BID for 12 Weeks on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers
Study Start Date : July 2010
Actual Primary Completion Date : February 2012
Actual Study Completion Date : February 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Dronedarone

Arm Intervention/treatment
Experimental: Dronedarone
Dronedarone 400 mg twice a day for 12 weeks
Drug: Dronedarone

Film-coated tablet

Oral administration under fed conditions (during breakfast and dinner)

Other Names:
  • Multaq®
  • SR33589

Placebo Comparator: Placebo
Placebo (for Dronedarone) twice a day for 12 weeks
Drug: Placebo (for Dronedarone)

Film-coated tablet strictly identical in appearance

Oral administration under fed conditions (during breakfast and dinner)





Primary Outcome Measures :
  1. Atrial Fibrillation (AF) Burden During the 12-week Treatment Period [ Time Frame: Baseline (before randomization), 4 weeks and 12 weeks after randomization ]

    AF burden, defined as the percent time a subject is in AF, was evaluated centrally by a Pacemaker Core Lab based on pacemaker interrogation reports including Electrogram (EGM) data provided by the Investigator.

    AF burden during the 12-week treatment period was defined as the duration-weighted average of AF burden collected at Week 4 and Week 12. It was calculated from the single available measurement when one measurement was missing.



Secondary Outcome Measures :
  1. AF Burden During the First 4 Weeks of Treatment and After 4-week Treatment [ Time Frame: 4 weeks and 12 weeks after randomization ]
    AF burden at each pacemaker interrogation as evaluated centrally by the Pacemaker Core Lab

  2. Average Ventricular Rate During AF Episodes [ Time Frame: Baseline (before randomization), 4 weeks and 12 weeks after randomization ]

    Ventricular rates of AF episodes were obtained from pacemaker interrogation and EGM review.

    The average ventricular rate during AF episodes in the 12-week treatment period was defined as the duration-weighted average of the ventricular rates collected at Week 4 and Week 12. It was calculated from the single available measurement when one measurement was missing.


  3. Atrial Fibrillation Severity Scale (AFSS) Scores [ Time Frame: Baseline (before randomization) and 12 weeks after randomization ]

    The University of Toronto Atrial Fibrillation Severity Scale is an instrument to assess the subject-perceived AF burden and AF symptom severity. It consists in a questionnaire plus a scoring algorithm.

    AF Burden score ranges from 3 to 30 and higher scores indicate greater AF burden.

    AF symptoms severity score ranges from 0 to 35 and higher scores indicate extremely severe AF symptoms.


  4. Incidence Rate of Electrical Cardioversion (or Overdrive Pacing) [ Time Frame: 12 weeks ]

    Electrical cardioversion is a procedure in which an electric shock is used to restore normal heart rhythm. Overdrive pacing is a procedure in which an artificial cardiac pacemaker is used to increase the heart rate in order to suppress certain arrhythmias.

    Incidence rate of electrical cardioversion (or overdrive pacing) is expressed as the number of participants that was cardioverted or paced during the study.



Other Outcome Measures:
  1. Overview of Adverse Events (AE) [ Time Frame: from first study drug intake up to 10 days after the last study drug intake ]
    AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Paroxysmal AF or atrial flutter (AFL) documented by evidence of AF/AFL and sinus rhythm within the prior 6 months;
  • AF burden ≥1% on pacemaker EGM interrogation at screening, with at least one episode of AF within the previous 28 days;
  • Programmable dual chamber pacemaker with lead placement no less than 3 months before screening, a minimum capability of storing 3 months or more of EGM data, and an expected remaining battery life of 1 year or more.

Exclusion criteria:

  • AF burden <1% on pacemaker EGM interrogation at screening;
  • None of the following cardiovascular risk factors: Age ≥70 years, hypertension, diabetes mellitus, prior cardiovascular accident or systemic embolism, left atrium diameter ≥50 mm by M-mode or 2D echocardiography, or left ventricular ejection fraction ≤0.40 by M-mode or 2D echocardiography, cardiac catheterization, or nuclear cardiac imaging;
  • Permanent AF;
  • Evidence of persistent AF (continuous AF activity lasting longer than 7 days);
  • Electrical cardioversion (or overdrive pacing) within 4 weeks prior to screening;
  • Cardiac ablation procedure within 3 months prior to screening;
  • Evidence of uncorrected atrial undersensing or oversensing documented in routine pacemaker evaluation at screening;
  • Pacemaker programming requirements for the study not clinically feasible, contraindicated, or could have posed risk;
  • Ongoing potentially dangerous symptoms when in AF/AFL such as angina pectoris, transient ischemic attacks, stroke, or syncope;
  • New York Heart Association (NYHA) Class IV heart failure or NYHA Class II or III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic within 4 weeks prior to screening;
  • Evidence of clinical instability including hypotension, unstable angina and hemodynamically significant obstructive valvular disease, hemodynamically significant obstructive cardiomyopathy, a cardiac operation, or revascularization procedure within 4 weeks prior to screening;
  • Noncardiovascular illness or disorder that could have precluded participation or severely limit survival including cancer with metastasis and organ transplantation requiring immune suppression;
  • Planned noncardiac or cardiac surgery or procedures including surgery for valvular heart disease, coronary artery bypass graft, percutaneous coronary intervention, cardiac transplantation or electrical cardioversion for AF/AFL;
  • Need for concomitant medication that were prohibited in this trial: Antiarrhythmics, drugs or products that are strong inhibitors of CYP3A, CYP3A inducers;
  • Chronic use of amiodarone within the 4 weeks prior to screening;
  • Use of Class I or Class III antiarrhythmics (other than amiodarone) within 5-half lives prior to screening;
  • Use of St John's wort, grapefruit juice, or drugs that prolong the QT interval and might have increased the risk of torsade de pointes;
  • Inability or unwillingness to comply with oral anticoagulation therapy, if indicated;
  • Bazett corrected QT interval interval ≥500 msec at screening (if in sinus rhythm);
  • Uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥ 100mmHg) at screening;
  • Uncorrected hypokalemia (serum potassium <3.5 mEq/L)
  • Severe hepatic impairment (ie, Child-Pugh Class C), abnormal liver function test defined as alanine aminotransferase (ALT), aspartate aminotransferase (AST), or bilirubin >2 X upper limit of normal (ULN), or renal impairment defined as serum creatinine >2.0 mg/dL at screening;
  • Uncontrolled diabetes mellitus (documented history of HbA1c >10% at the most recent assessment prior to screening);
  • Pregnant woman or woman of childbearing potential not on adequate birth control;
  • Breastfeeding woman;
  • Previous (within 2 months prior to screening) or current participation in another clinical trial with an investigational drug (under development) or investigational device.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01135017


  Show 92 Study Locations
Sponsors and Collaborators
Sanofi
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi

Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT01135017     History of Changes
Other Study ID Numbers: DRONE_L_04316
U1111-1117-0024 ( Other Identifier: UTN )
First Posted: June 2, 2010    Key Record Dates
Results First Posted: April 1, 2013
Last Update Posted: April 11, 2013
Last Verified: April 2013

Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Dronedarone
Anti-Arrhythmia Agents